Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Enliven Therapeutics, Inc. (ELVN) had Return on Tangible Equity of -5.21% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-23.63M |
|
-- |
|
-- |
|
$27.82M |
|
$-27.82M |
|
$4.20M |
|
$-23.63M |
|
$-23.63M |
|
$-23.63M |
|
$-23.63M |
|
$-23.63M |
|
$-23.63M |
|
$-27.82M |
|
$-27.54M |
|
62.80M |
|
62.80M |
|
$-0.38 |
|
$-0.38 |
|
| Balance Sheet Financials | |
$463.14M |
|
$0.02M |
|
$1.72M |
|
$464.85M |
|
$11.49M |
|
-- |
|
-- |
|
$11.49M |
|
$453.37M |
|
$453.37M |
|
$453.37M |
|
60.89M |
|
| Cash Flow Statement Financials | |
$-19.29M |
|
$42.53M |
|
$10.05M |
|
$98.90M |
|
$132.18M |
|
$33.29M |
|
$7.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
40.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.21% |
|
|
Return on Tangible Equity |
-5.21% |
-5.08% |
|
-5.21% |
|
$7.45 |
|
$-0.31 |
|
$-0.31 |
|